Transforming patient care through translational research

Increased long-term risk of breast cancer with high intra-tumour ER hetrogeneity

GTX-024 for androgen receptor positive breast cancer

Final overall survival analysis of MONARCH 1

Redefining tamoxifen for breast cancer

Treatment choices for HER2 amplified colorectal cancer

Final results of the HERACLES trial in HER2-amplified colorectal cancer

Personalising breast cancer therapies

Five years of letrozole does not improve disease free survival for pretreated HR positive breast cancer

Oestrogen deprivation inffective with chemo for HR/HER positive breast cancer

Expert discussion on CDK 4/6 inhibition in breast cancer

Extended adjuvant endrocine therapy with letrozole after aromatase inhibition